Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is projected to generate revenue of 2.649 billion RMB in 2025, representing a decline of 5.8% year-over-year, with adjusted net profit expected to be 209 million RMB, down 49.7% year-over-year. The decline is attributed to an increase in the proportion of artificial insemination (IUI) affecting the number of egg retrieval cycles and pricing, along with zero markup on drug costs. However, there is a significant improvement expected in the second half of the year [1][5] - For 2026, the outlook is positive, driven by the implementation of the California commercial insurance law SB729, which is expected to catalyze a 38% year-over-year increase in cycle numbers in January and February. The new facility in Shenzhen is also expected to contribute positively, with a projected 18% year-over-year increase in cycle numbers [1][2] Summary by Sections Domestic Business - The revenue in the Greater Bay Area is expected to decline by 8.8% to 420 million RMB in 2025, primarily due to a higher proportion of lower-cost IUI cycles and delays in the relocation of the Shenzhen facility. However, a double-digit year-over-year growth is anticipated for the Shenzhen region in 2026, supported by a significant increase in capacity and higher customer pricing through premium services [2][3] Overseas Business - The HRC Fertility business in the U.S. is expected to benefit from the acceleration of commercial insurance coverage, with a projected revenue increase of 5.1% year-over-year in 2025. The implementation of SB729 is expected to enhance cycle numbers significantly, with a 38% year-over-year increase in January and February [3][4] Financial Forecast and Valuation - The company is expected to achieve adjusted EPS of 0.11 RMB in 2026, with a target price set at 3.25 HKD, reflecting a 26x PE ratio. This valuation considers the potential positive impact of the U.S. insurance coverage on revenue and pricing strategies [5][11]

Core Insights - The company has received a Class III medical device registration certificate for its Geri embryo culture medium from the National Medical Products Administration of China, marking a significant milestone in its product development [1] - The Geri embryo culture medium has already obtained certifications from CE, FDA, and TGA, indicating its international compliance and readiness for clinical use [1][2] - The product addresses the challenges faced by older patients in embryo cultivation through its antioxidant formula and stable osmotic pressure environment, enhancing clinical pregnancy rates [2] Product Development - The Geri embryo culture medium is designed specifically to tackle fertility issues in older patients, featuring a "triple antioxidant protection network" that mitigates oxidative stress in older embryos [2] - The inclusion of human serum albumin and long-term stability simplifies laboratory operations and ensures a stable cultivation environment [2] - International clinical validation shows that the combination of Geri embryo culture medium with the Geri wet incubator and AI embryo assessment system significantly improves the quality blastocyst rate and clinical pregnancy rate [2] Market Position - The approval of the Geri embryo culture medium signifies the company's transition from technology introduction to localized production, filling a gap in the domestic high-end assisted reproductive consumables market [2] - The company is the first in China to hold FDA, CE, TGA, and NMPA certifications, establishing a strong competitive position in the industry [2] - With core PGT technology and self-supply capabilities, the company has covered most PGT licensed institutions nationwide and established numerous localized laboratories, creating a sustainable ecological barrier [2]

Core Viewpoint - The approval of Geri embryo culture medium by the National Medical Products Administration (NMPA) in China marks a significant milestone for the company, enabling it to address the challenges faced by older patients in embryo cultivation and filling a gap in the domestic high-end assisted reproductive consumables market [1][2]. Group 1 - The Geri embryo culture medium received a Class III medical device registration certificate from the NMPA on February 25, 2026 [1]. - Prior to this approval, the Geri embryo culture medium had already obtained certifications from the European Union (CE), the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA) [1]. - The core technology of the Geri embryo culture medium is derived from the Sydney IVF Center, and it combines with the Geri wet incubator and AI embryo assessment system to enhance clinical practice in China [1]. Group 2 - The technology focuses on creating a systematic solution for fertility challenges faced by older patients, featuring a "triple antioxidant protection network" that effectively addresses oxidative stress in older embryos [2]. - The combination of the culture medium with the Geri wet incubator and AI embryo assessment system has been clinically validated to significantly improve the rates of quality blastocysts and clinical pregnancy, providing strong support for older fertility [2]. - The approval signifies a critical transition for the company from technology introduction to localized production, making it the first Chinese enterprise to hold FDA, CE, TGA, and NMPA certifications [2].

Core Viewpoint - The approval of Geri embryo culture medium by the National Medical Products Administration (NMPA) in China marks a significant milestone for the company, establishing it as the first Chinese enterprise to obtain FDA, CE, TGA, and NMPA certifications for high-end assisted reproductive materials [1][2]. Group 1: Product Approval and Certifications - The Geri embryo culture medium received its Class III medical device registration certificate from the NMPA on February 25, 2026 [1]. - Prior to this approval, the Geri embryo culture medium had already obtained certifications from the European Union (CE), the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA) [1]. Group 2: Technological Advantages - The core technology of the Geri embryo culture medium addresses fertility challenges for older patients through a systematic solution, featuring a "triple antioxidant protection network" that effectively mitigates oxidative stress in older embryos [2]. - The product simplifies laboratory operations and ensures a stable culture environment by incorporating human serum albumin and ultra-long-term stability [2]. Group 3: Clinical Impact and Market Position - International clinical validation indicates that the Geri embryo culture medium, when combined with the Geri wet incubator and AI embryo assessment system, significantly enhances the rates of high-quality blastocysts and clinical pregnancy [2]. - The approval signifies a critical transition from technology introduction to localized production, filling a gap in the domestic market for high-end assisted reproductive consumables [2]. - The company has established a strong presence across most PGT licensed institutions in China and operates numerous localized laboratories, creating a sustainable ecological barrier for continuous innovation [2].

Suzhou Basecare Medical Corporation Limited 蘇 州 貝 康 醫 療 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2170） 自願公告 Geri胚胎培養液（Gems胚胎培養液系列產品之一） 獲國家藥監局頒發醫療器械註冊證 本公告由蘇州貝康醫療股份有限公司（「本公司」，連同其子公司統稱「本集團」） 自願刊發，以告知本公司股東及潛在投資者有關本集團業務的最新發展。 本公司董事會（「董事會」）欣然宣佈，本公司的Geri胚胎培養液（Gems胚胎培養 液系列產品之一）於2026年2月25日獲得中國國家藥品監督管理局（「國家藥監局」） 頒發的三類醫療器械註冊證（註冊證號：國械註進20263180071）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 此次獲批標誌著公司實現從引進技術到本土化生產的關鍵跨越，填補國產高 端輔助生殖耗材空白，成為首 ...

Core Viewpoint - The study conducted by Zhejiang University and published in the British Medical Journal indicates that routine supplementation of Vitamin D does not significantly improve live birth rates in women with Polycystic Ovary Syndrome (PCOS) undergoing IVF-ET, despite increasing Vitamin D levels in the blood [1][4][6]. Group 1: Background and Context - PCOS is one of the most common endocrine and metabolic disorders among women of reproductive age, with a global prevalence of approximately 5% to 20% [2]. - Vitamin D is often suggested as a potential aid in fertility due to its association with bone health and its receptors being present in the ovaries, endometrium, and placenta [2][3]. - The incidence of Vitamin D deficiency among women with PCOS can be as high as 70%-80%, with severe deficiency affecting around 40% of this population [2]. Group 2: Study Design and Methodology - The research was a multi-center, randomized, double-blind, placebo-controlled trial involving 876 women with PCOS planning to undergo IVF-ET [4][5]. - Participants were randomly assigned to receive either 4000 IU of Vitamin D daily or a placebo until the trigger day for egg retrieval, with a maximum duration of three months [4]. Group 3: Key Findings - The Vitamin D group showed an increase in average blood Vitamin D levels from 16.5 ng/mL (deficient) to 32.3 ng/mL (sufficient), while the placebo group remained unchanged [5]. - The live birth rate in the Vitamin D group was 52.0%, compared to 50.2% in the placebo group, with no statistically significant difference observed [6]. - Other key indicators such as the number of eggs retrieved, embryo quality, and pregnancy rates showed no significant differences between the two groups [6]. Group 4: Implications and Recommendations - The study suggests that routine Vitamin D supplementation should not be considered a standard practice for women with PCOS undergoing assisted reproductive technology [6][7]. - It emphasizes the importance of personalized treatment plans focusing on evidence-based practices rather than relying on anecdotal recommendations [7][8]. - The research also highlights the potential benefits of correcting Vitamin D deficiency for improving insulin resistance and metabolic health, even if it does not directly enhance live birth rates [7][8].

Core Viewpoint - The company, Canar Medical, is experiencing a decline in revenue and profit, with a significant reliance on overseas sales benefiting from the depreciation of the RMB [3][7]. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018 [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, while the average circulating shares per person increased by 2.13% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 13, Canar Medical's stock price fell by 0.06%, with a trading volume of 61.59 million yuan and a turnover rate of 2.52%, resulting in a total market capitalization of 3.911 billion yuan [1]. - The stock has seen a net inflow of 2.74 million yuan from major investors today, with a ranking of 19 out of 138 in its industry, although the industry overall has experienced a net outflow of 461 million yuan [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 28.95 yuan, with the stock price currently near a support level of 31.49 yuan, indicating potential for a rebound if this level holds [6].

Core Viewpoint - The company, Canar Medical, has seen a stock price increase of 3.14% with a trading volume of 140 million yuan and a market capitalization of 3.897 billion yuan, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction [1][2][3]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][7]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. - As of January 30, the number of shareholders is 6,957, a decrease of 2.08%, with an average of 10,872 circulating shares per person, an increase of 2.13% [7]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Market Position and Trends - The company has a high overseas revenue ratio of 90.61%, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 28.77 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a support level of 31.49 yuan, which is critical for potential rebound or further decline [6].

Core Viewpoint - Wanfu Biological experienced a stock price increase of 12.81% year-to-date, with a notable rise of 4.11% in the last five trading days, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders was 134 million yuan, down 69.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.213 billion yuan, with 601 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wanfu Biological was 42,400, a decrease of 5.59% from the previous period. The average number of circulating shares per shareholder increased by 5.94% to 10,160 shares [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.1927 million shares, a reduction of 1.3623 million shares from the previous period. The Southern Zhongzheng 1000 ETF held 2.6442 million shares, down by 20,900 shares [3]. Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary services (0.04%) [1]. Market Position - Wanfu Biological is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics. The company is associated with various concept sectors, including avian influenza drugs, assisted reproduction, anti-influenza, gene sequencing, and the pet economy [1].

Core Viewpoint - Tongce Medical's stock has shown a positive trend with a year-to-date increase of 12.41%, reflecting strong performance in the medical service sector [1][2]. Group 1: Stock Performance - As of January 21, Tongce Medical's stock price reached 45.20 CNY per share, with a market capitalization of 20.217 billion CNY [1]. - The stock has experienced a 4.15% increase over the last five trading days, a 10.19% increase over the last 20 days, and a 6.60% increase over the last 60 days [1]. - The company has seen a net outflow of 12.52 thousand CNY in principal funds, with significant buying and selling activity from large orders [1]. Group 2: Financial Performance - For the period from January to September 2025, Tongce Medical reported a revenue of 2.29 billion CNY, representing a year-on-year growth of 2.56%, and a net profit attributable to shareholders of 514 million CNY, up 3.06% year-on-year [2]. - The company has distributed a total of 392 million CNY in dividends since its A-share listing, with 340 million CNY distributed over the past three years [3]. Group 3: Shareholder Structure - As of January 10, the number of shareholders for Tongce Medical decreased to 90,000, while the average number of circulating shares per person increased by 8.89% to 4,969 shares [2]. - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with some shareholders reducing their holdings [3].